Stress‑effector priming: Intermittent TOR inhibition gates FOXO3‑driven longevity without exogenous hormesis
Hypothesis
Constitutive activation of the stress‑responsive transcription factor FOXO3 does not extend lifespan unless cells experience periodic, low‑amplitude inhibition of TOR signaling.
Mechanistic Rationale
Hormetic interventions such as fasting or exercise transiently suppress TOR while activating FOXO3‑dependent programs (DAF‑16/FOXO, HSPs, SODs) [1]. These events are short‑lived; sustained FOXO3 activity alone leads to feedback inhibition via up‑regulation of IGF‑1 signaling and mTORC1 re‑activation [2]. Blagosklonny’s Hormesis A/B framework distinguishes lifespan extension from mere stress tolerance, positioning TOR inhibition as the driver of longevity [3]. Therefore, the longevity benefit of hormesis arises from a gate whereby TOR inhibition permits FOXO3 effectors to act without triggering compensatory growth pathways.
Testable Predictions
-
Animals expressing a ligand‑independent, constitutively active FOXO3 mutant will show no increase in median lifespan compared with wild‑type when TOR activity remains basal.
-
Combining the same FOXO3 mutant with an intermittent rapamycin regimen (e.g., 5 days on/2 days off) will synergistically extend lifespan beyond either manipulation alone.
-
Transcriptomic profiling will reveal that intermittent TOR inhibition prevents the induction of negative feedback regulators (e.g., IGF‑1, Akt) that otherwise blunt FOXO3‑target gene expression.
Experimental Design
- Generate a knock‑in mouse line expressing a FOXO3‑Δ256 mutant (constitutively nuclear, AKT‑phosphorylation resistant) under its endogenous promoter.
- Cohorts: (a) wild‑type control, (b) FOXO3 mutant alone, (c) wild‑type + intermittent rapamycin (2 mg/kg i.p., 5 days/week), (d) FOXO3 mutant + intermittent rapamycin.
- Monitor survival, healthspan metrics (grip strength, glucose tolerance), and collect liver and muscle samples at 6, 12, and 18 months for RNA‑seq and phospho‑S6 immunoblotting.
Potential Outcomes
If hypothesis is correct, group (d) will display significant lifespan extension and improved healthspan, whereas groups (b) and (c) will show modest or no benefit. Molecularly, group (d) will maintain elevated FOXO3 targets without concomitant rise in IGF‑1/Akt signaling, confirming that periodic TOR inhibition gates effector activity. Failure to observe synergy would falsify the model, suggesting that constitutive FOXO3 activity suffices or that additional stress‑signaling layers are required.
References
[1] Hormesis triggers adaptive responses like upregulation of DAF‑16/FOXO, heat shock proteins, and antioxidant enzymes – https://pmc.ncbi.nlm.nih.gov/articles/PMC7041774/ [2] These are transient signaling events rather than sustained repair – https://pmc.ncbi.nlm.nih.gov/articles/PMC3249451/ [3] Blagosklonny’s framework divides hormesis into Hormesis A and Hormesis B – https://www.aging-us.com/article/100411/text